Why Pharma Company Amarin Shares Are Zooming Today

    Date:

    Loading…

    Loading…

    Amarin Corp PLC AMRN shares are trading by around 28% after the company reported preliminary Q4 FY23 results.

    AMRN expects revenue of $72 million-$74 million (vs. consensus $62.03 million) for Q4 and $304 million-$306 million (vs. $294.16 million) for FY23.

    The company ended 2023 with cash of around $321 million and investments, with a positive cash flow of about $10 million. 

    Amarin says it is on track to deliver $40 million of annual savings based on the reduction in force announced in July 2023. 

    Share Buyback: Amarin entered into a conditional share repurchase agreement with Cantor Fitzgerald & Co. to buy up to $50 million of its ordinary shares in American depository shares (ADSs). 

    Amarin anticipates completing this initiative by the end of Q2 2024, with share repurchases commencing shortly after.

    Patrick Holt, President & CEO of Amarin said, “We enter 2024 with a number of positives: we have a solid cash position and no debt; our European business is showing early signs of progress following new leadership and a new strategy; our U.S. business continues to retain IPE market leadership and is in a solid position with exclusive contracts to start 2024; and our partners in the Rest of World (ROW) are advancing commercialization and market access efforts.”
     

    Price Action: AMRN shares are up 28% at $1.24 on the last check Wednesday. 

    Loading…

    Loading…

    Go Source

    Chart

    Sign up for Breaking Alerts

    Share post:

    Popular

    More like this
    Related

    Highlights from the IBKR Quant Blog – May 2024

    Your Privacy When you visit any website it may use...

    Not With a Bang But a Whimper

    Your Privacy When you visit any website it may use...

    Take Notes: Orbisa on GME

    Your Privacy When you visit any website it may use...

    Global Equity Funds Rally As Fed Rate Cuts Loom

    Your Privacy When you visit any website it may use...